TY - JOUR T1 - Belgian prospective, multicenter, observational study of patients with malignant pleural mesothelioma treated with pemetrexed plus platinum JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - 1702 AU - Kristiaan Nackaerts AU - Marc Lambrechts AU - Frederique Bustin AU - Luc Van Zandweghe AU - Benoît Colinet AU - Michiel Thomeer AU - Jean François Rosier AU - Kees Kraaij AU - Yulia D'yachkova Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/1702.abstract N2 - Introduction Pemetrexed (pem) + cisplatin (cis) is the only chemotherapy regimen with marketing authorization for treating chemonaïve patients (pts) with unresectable malignant pleural mesothelioma (MPM). Aims and objectives The study collected pt characteristics and survival data related to pem use at request of Belgian authorities. Methods Study of pts with unresectable MPM starting 1st-line treatment (tx) with pem+cis. Authorities set sample size (n=100). Analyses used standard descriptive summaries and Kaplan-Meier method for survival. Results 111 pts receiving ≥1 dose of pem were observed from Aug 2006 to Nov 2012. Median duration of follow-up was 14.7 months; pts treated for median 4.6 months (6 cycles; maximum 44 cycles). Overall, 29 pts (26.1%) received carboplatin not cis: 7 at 1st cycle and 22 later. Other results are in the table. Tx was discontinued for completion of planned cycles with partial response/stable disease (36.0%), disease progression (28.8%) and adverse event/toxicity (21.6%). By study end, 96 pts (86.5%) had died, 10 (9.0%) were lost to follow-up and 5 (4.5%) were alive and censored. Conclusions Pem was used in accordance with its label in the majority of pts who received platinum-pem 1st-line tx for unresectable MPM in routine practice.View this table: ER -